Clinical Trial Detail

NCT ID NCT02572167
Title A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Seattle Genetics, Inc.
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Nivolumab

Age Groups: adult

No variant requirements are available.